Val8-glucagon-like peptide-1 protects against A1-40-induced impairment of hippocampal late-phase long-term potentiation and spatial learning in rats
3,4 This receptor and its agonists hold significant therapeutic potential, reshaping the treatment approaches for multiple diseases, including diabetes, cardiovascular disorders, and neurodegenerative diseases
[DOI] [PubMed] [Google Scholar] 18.Pederson RA, Brown JC
doi: 10.3390/ijms20205064 200 ChangYFZhangDHuWMLiuDXLiL
These limitations include fatigue, shortness of breath, reduced exercise capacity, and limb swelling
Brief Introduction and Physiological Function of Glucagon Like Peptide-1 Receptor Agonists Glucagon like peptide-1 (GLP-1) is the second incretin identified in 1983